Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116-Reference-Cited by-同舟云学术

Development of a Formulation and In Vitro Evaluation of a Pulmonary Drug Delivery System for a Novel Janus Kinase (JAK) Inhibitor, CPL409116

Published:2024-08-31 Issue:9 Volume:16 Page:1157
ISSN:1999-4923
Container-title:Pharmaceutics
language:en
Short-container-title:Pharmaceutics

Author:

Rzewińska Aleksandra¹²^ORCID,Szlęk Jakub³^ORCID,Dąbrowski Damian⁴,Juszczyk Ewelina¹^ORCID,Mróz Katarzyna¹,Räikkönen Heikki⁵,Siven Mia⁶⁷^ORCID,Wieczorek Maciej⁸,Dorożyński Przemysław²⁹^ORCID

Affiliation:

1. Finished Dosage Forms Department, Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland

2. Department of Drug Technology and Pharmaceutical Biotechnology, Faculty of Pharmacy, Medical University of Warsaw, Banacha 1, 02-097 Warszawa, Poland

3. Chair and Department of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland

4. Chair of Analytical Chemistry, Faculty of Chemistry, Warsaw University of Technology, Noakowskiego 3, 00-664 Warszawa, Poland

5. Faculty of Pharmacy, University of Helsinki, Viikinkaari 5, 00014 Helsinki, Finland

6. Division of Pharmaceutical Chemistry and Technology, Faculty of Pharmacy, University of Helsinki, Viikinkaari 5 E, 00014 Helsinki, Finland

7. Helsinki Institute of Sustainability Science HELSUS, University of Helsinki, 00014 Helsinki, Finland

8. Research and Development Center, Celon Pharma S.A., Marymoncka 15, 05-052 Kazuń Nowy, Poland

9. Department of Inorganic and Analytical Chemistry, Faculty of Pharmacy, Jagiellonian University Medical College, Medyczna 9, 30-688 Kraków, Poland

Abstract

The pursuit of targeted therapies for cytokine-dependent diseases has led to the discovery of Janus kinase (JAK) inhibitors, a promising class of drugs. Among them, CPL409116, a selective dual JAK and rho-associated protein kinase inhibitor (ROCK), has demonstrated potential for treating conditions such as pulmonary fibrosis exacerbated by the COVID-19 pandemic. This study investigated the feasibility of delivering CPL409116 via inhalation, with the aim of minimizing the systemic adverse effects associated with oral administration. Two micronization methods, jet milling and spray drying, were assessed for CPL409116, with spray drying chosen for its ability to produce an amorphous form of the compound. Moreover, parameters such as the mixing energy, drug load, and force control agent significantly influenced the fine particle fraction (FPF), a critical parameter for pulmonary drug delivery. This study provides insights into optimizing the formulation parameters to enhance the delivery efficiency of CPL409116 to the lungs, offering potential for improved therapeutic outcomes in cytokine-dependent pulmonary diseases.

Funder

Celon Pharma S.A.

European Union’s Horizon 2020 Research and Innovation program

Smart Growth Operational Programme POIR 4.2

Jagiellonian University

Publisher

MDPI AG

Link

https://www.mdpi.com/1999-4923/16/9/1157/pdf

Reference49 articles.

1. The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention;Schwartz;Annu. Rev. Med.,2015

2. Janus Kinases in Immune Cell Signaling;Ghoreschi;Immunol. Rev.,2009

3. The JAK-STAT Pathway at 30: Much Learned, Much More to Do;Philips;Cell,2022

4. Schwartz, D.M., Kanno, Y., Villarino, A., Ward, M., Gadina, M., and O’Shea, J.J. (2024, July 02). JAK Inhibition as a Therapeutic Strategy for Immune and Inflammatory Diseases. Available online: https://sci-hub.se/10.1038/nrd.2017.201.

5. IL-6 Biology: Implications for Clinical Targeting in Rheumatic Disease;Calabrese;Nat. Rev. Rheumatol.,2014